Dermatology · Indianapolis, IN
NPI
1497758627
Since 2005
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
7910 N Shadeland Ave
Indianapolis, IN, 46250
Phone (317) 516-5000
Groups this clinician bills Medicare through
Medicare paid, 2024
$955K
15,518 services
Medicare patients, 2024
2,756
Average age 75
Drug cost, 2024
$2.2M
3,691 prescriptions
Company payments, 2025
$102K
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kenneth W Dawes was code J3245 (injection, tildrakizumab, 1 mg), 3,300 times for 18 patients. In total Kenneth W Dawes billed 15,518 services in 103 codes, and Medicare paid $955K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-04-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3245 Injection, tildrakizumab, 1 mg | Office | 3,300 | 18 | $107.87 | $356K |
| 17003 Destruction Skin Lesion | Office | 2,872 | 636 | $4.56 | $13K |
| 99213 Office E&M - Established | Office | 1,651 | 1,371 | $53.03 | $88K |
| 99214 Office E&M - Established | Office | 1,556 | 1,210 | $78.14 | $122K |
| 17000 Destruction Skin Lesion | Office | 1,194 | 941 | $34.25 | $41K |
| 88305 Surgical Pathology Examination | Office | 631 | 404 | $51.45 | $32K |
| 17110 Destruction Skin Lesion | Office | 608 | 537 | $66.51 | $40K |
| 96910 Skin | Office | 579 | 29 | $83.90 | $49K |
| 11301 Removal or Shaving of Skin Growth | Office | 239 | 205 | $66.91 | $16K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 218 | 62 | $0.72 | $158 |
| 11102 Skin Biopsy | Office | 197 | 188 | $57.10 | $11K |
| 99203 Office E&M - New | Office | 122 | 122 | $58.19 | $7,099 |
| 17261 Destruction Skin Lesion | Office | 114 | 97 | $86.64 | $9,877 |
| 96920 Skin | Office | 107 | 12 | $114.28 | $12K |
| 17262 Destruction Skin Lesion | Office | 96 | 80 | $110.20 | $11K |
By year: 2022 $706K for 13,123 services; 2023 $814K for 14,087 services; 2024 $955K for 15,518 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88305 Surgical Pathology Examination | 631 | 404 | $51.45 | $32K |
| 88304 Surgical Pathology Examination | 31 | 29 | $30.42 | $943 |
| 87220 General Laboratory | 21 | 21 | $4.18 | $87.78 |
Medicare prescription drug claims, 2024
In 2024, the drug Kenneth W Dawes prescribed most often to Medicare patients was Ketoconazole, with 407 prescriptions and refills. In total Kenneth W Dawes wrote 3,691 Medicare prescriptions that cost $2.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ketoconazole Generic | 407 | 461 | 206 | $7,034 |
| Hydrocortisone Generic | 403 | 441 | 262 | $2,342 |
| Fluocinonide Generic | 392 | 441 | 243 | $16K |
| Clobetasol Propionate Generic | 216 | 232 | 122 | $8,966 |
| Triamcinolone Acetonide Generic | 213 | 252 | 150 | $1,980 |
| Doxycycline Hyclate Generic | 153 | 181 | 62 | $2,333 |
| Fluorouracil Generic | 126 | 130 | 117 | $10K |
| Clindamycin Phosphate Generic | 117 | 135 | 58 | $4,469 |
| Valacyclovir Valacyclovir Hcl | 106 | 161 | 58 | $3,555 |
| Metronidazole Generic | 87 | 120 | 62 | $6,317 |
| Dupixent Pen Dupilumab | 73 | 73 | Under 11 | $271K |
| Minoxidil Generic | 60 | 134 | 19 | $544 |
| Hydroxychloroquine Sulfate Generic | 58 | 82 | 12 | $976 |
| Selenium Sulfide Generic | 58 | 61 | 23 | $499 |
| Fluconazole Generic | 56 | 70 | 32 | $740 |
Brand drugs: 467 claims; generic drugs: 3,224 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kenneth W Dawes $102K ($18K in general payments such as food, travel and fees and $84K for research) from 25 companies. The largest payer was Takeda Pharmaceuticals U.S.A., Inc. with $84K.
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 17 | $84K |
| Pfizer Inc. PFE | 33 | $17K |
| Abbvie Inc. ABBV | 25 | $355 |
| Novartis Pharmaceuticals Corporation NVS | 26 | $267 |
| Arcutis Biotherapeutics, Inc. ARQT | 4 | $163 |
| Regeneron Healthcare Solutions, Inc. REGN | 3 | $158 |
| Amgen Inc. AMGN | 14 | $148 |
| Lilly USA, LLC LLY | 5 | $107 |
| Janssen Biotech, Inc. JNJ | 3 | $99.13 |
| UCB, Inc. UCB.BR | 4 | $81.41 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.